The limited evidence for the efficacy of Aduhelm raises the question of whether its large impact on health spending is justified.

The U.S. Food and Drug Administration recently approved a new drug for treatment of Alzheimer’s disease, despite concerns about both the cost and efficacy.

Although Biogen, the manufacturer, tested Aduhelm on patients with mild cognitive impairment, the FDA approved its use more broadly for the more than six million Americans currently diagnosed with Alzheimer’s. The drug is administered through intravenous infusion at an annual cost of $56,000 per patient, a non-retail expenditure that will be borne primarily by Medicare Part B. Several researchers recently analyzed estimated expenditures on Aduhelm for Altarum, a nonprofit health care research and consulting organization.

Complete your profile to continue reading and get FREE access to, part of your ALM digital membership.

Your access to unlimited content isn’t changing.
Once you are an ALM digital member, you’ll receive:

  • Critical information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and events.
  • Access to other award-winning ALM websites including and

Already have an account?



Join BenefitsPRO

Don’t miss crucial news and insights you need to navigate the shifting employee benefits industry. Join now!

  • Unlimited access to - your roadmap to thriving in a disrupted environment
  • Access to other award-winning ALM websites including and
  • Exclusive discounts on and ALM events.

Already have an account? Sign In Now
Join BenefitsPRO

Copyright © 2023 ALM Global, LLC. All Rights Reserved.